You are here

2017 NCH Statement Regarding FDA Draft Guidance

December 19, 2017
The FDA just released draft guidance for Drug Products labeled as Homeopathic.  
NCH issued the following response:

The National Center for Homeopathy supports the FDA’s efforts to ensure safety and good manufacturing practices in the industry.  We are committed to working with industry partners to protect consumer access to homeopathic medicines, and we are hopeful that this action will not impede access.  Homeopathic medicines are safe, gentle and effective when products are manufactured in accordance with HPUS (Homoeopathic Pharmacopoeia of the United States) guidelines under CGMPs (Current Good Manufacturing Practices).  We welcome the opportunity to educate consumers and healthcare professionals about the unique aspects of homeopathic medicine. 

The National Center for Homeopathy (NCH) provides education and builds awareness while advocating for access to homeopathy as a safe, effective and affordable system of medicine.